Recent Updates
Recently added Catalysts
LXRX Positive Sentiment

Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference

Key Takeaway: Lexicon Pharmaceuticals will participate in a fireside chat at the Jefferies 2025 London Healthcare Conference on November 18. The event will provide an opportunity for company management to discuss their innovative medicines and pipeline. Lexicon focuses on genomics and has advanced multiple medicines to market, targeting various diseases.
Price reaction · baseline $1.42 (2025-11-10 close) · hit pre-market · clean, no other LXRX news in the window
day 0 close · peak
+9.9%
day 1
+8.5%
day 3
+4.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Lexicon Pharmaceuticals is actively engaging with investors.
  • Participation in the Jefferies 2025 London Healthcare Conference highlights company visibility.
  • The company has a strong pipeline of drug candidates in various therapeutic areas.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+111%
120-day peak, hindsight
Typical move
11%
average across 13 past catalysts
Cash runway
~61 mo
Minimal dilution risk
Lead asset
Sotagliflozin
Phase 3 · Type 1 Diabetes Mellitus

Full Press Release Details

THE WOODLANDS, Texas, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18 at 5:00 p.m. GMT (12:00 p.m. EST).
The live events and replays of the presentations can be accessed via the Events page of the Company’s website athttps://investors.lexpharma.com/.
About Lexicon PharmaceuticalsLexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon has advanced multiple medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, obesity, cardiology, diabetes and other indications. For additional information, please visitwww.lexpharma.com.

For Investor and Media Inquiries:Lisa DeFrancescoLexicon Pharmaceuticals, Inc.lexinvest@lexpharma.com

Frequently Asked Questions

When is Lexicon Pharmaceuticals participating in the conference?

Lexicon Pharmaceuticals will participate on November 18 at 5:00 p.m. GMT.

How can I access the conference presentations?

The live events and replays can be accessed via the Events page on Lexicon's website.

What is Lexicon Pharmaceuticals' focus?

Lexicon focuses on pioneering medicines through genomics and has a diverse pipeline.

What therapeutic areas does Lexicon target?

Lexicon targets heart failure, neuropathic pain, obesity, cardiology, and diabetes.

Last updated: Nov 11, 2025